Biophytis Reports 2020 Full Year Results. Read the Press Release

Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) following Regulatory Authorities approvals in France and Belgium. Read the Press Release

Biophytis Announces Closing of ADS Offering on Nasdaq Capital Market. Read the Press Release

Biophytis Announces Trading Resumption of its Ordinary Shares and Share Warrants on Euronext.Read the Press Release 

Biophytis Announces Temporary Trading Halt of its Shares and Share Warrants on Euronext Growth. Read the Press Release

Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market. Read the Press Release

Biophytis Announces the Launch of its Proposed Public Offering and Nasdaq Listing. Read the Press Release

Biophytis Announces the Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”). Read the Press Release

Biophytis Announces Public Filing of a Registration Statement for Proposed Initial Public Offering in the United States. Read the Press Release

Biophytis Announces Plan to Publicly File Later Today Registration Statement for Proposed Initial Public Offering in the United States. Read the Press Release

Biophytis receives DMC recommendation for starting recruitment for Part 2 of its Phase 2-3 COVA study in COVID-19. Read the Press Release

Biophytis to Participate in Upcoming Investor & Partnering Conferences During J.P. Morgan Week 2021. Read the Press Release